Skip to main content
    J

    Jade Biosciences, Inc. (JBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.34
    -0.80 (-4.99%)

    Market Cap: $1.03B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Jade Biosciences, Inc. (JBIO) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Jade Biosciences reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$127.41M, operating cash flow was -$94.69M and free cash flow was -$94.89M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$35.05M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $113.54M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Research and development$93.12M$53.19M$64.22M$38.62M$14.99M$7.94M
    Operating income-$113.54M-$74.60M-$81.41M-$53.24M-$23.02M-$8.89M
    Net income-$127.41M-$69.63M-$75.52M-$103.02M-$22.96M-$19.22M
    EBITDAN/AN/AN/A-$52.41M-$22.93MN/A
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Gross profit$0$0$0-$9.00K$0$0$0-$8.00K$0$0$0-$28.00K
    Operating income-$39.64M-$58.92M-$43.45M-$54.98M-$27.40M-$27.78M-$23.38M-$6.40M-$15.55M-$26.16M-$24.62M-$22.07M
    Net income-$35.05M-$55.77M-$40.37M-$67.58M-$25.18M-$32.13M-$38.17M-$5.43M-$16.87M-$24.77M-$23.19M-$20.41M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded long-term debt of $0 by $88.44M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$349.78M$72.80M$127.42M$135.30M$175.36M$4.71M
    Current assets$348.82M$69.65M$124.23M$131.50M$174.33M$4.68M
    Cash and equivalents$88.44M$69.39M$23.49M$22.40M$54.20M$4.57M
    Total liabilities$17.26M$119.60M$17.96M$8.56M$2.94M$1.77M
    Short-term debtN/A$417.00K$420.00K$385.00K$192.00KN/A
    Long-term debt$0$107.60MN/AN/AN/AN/A
    Shareholder equity$332.52M-$46.80M$109.46M$126.74M$172.42M-$13.34M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$486.39M$472.11M$319.43M$349.78M$202.45M$223.97M$77.53M$80.33M$90.96M$111.69M$106.82M$127.42M
    Total liabilities$30.89M$32.20M$22.97M$17.26M$23.10M$22.41M$2.49M$3.90M$10.47M$17.30M$15.92M$17.96M
    Cash and equivalents$80.39M$107.25M$55.09M$88.44M$50.11M$220.94M$44.22M$33.75M$31.11M$31.07M$9.12M$23.49M
    Shareholder equity$455.50M$439.92M$296.46M$332.52M$179.35M$201.56M$75.05M$76.43M$80.49M$94.40M$90.90M$109.46M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$94.69M-$71.20M-$56.78M-$39.12M-$27.40M-$7.86M
    Capital expenditures$196.00K$0$142.00K$195.00K$181.00K$0
    Free cash flow-$94.89M-$71.20M-$56.92M-$39.32M-$27.58M-$7.86M
    Share repurchasesN/A$307.00K$234.00K$371.00K$0N/A
    Investing cash flow-$247.01M$56.03M$11.88M$6.93M-$113.43M$0
    Financing cash flow$360.77M$25.43M$46.00M$396.00K$190.46M$8.92M
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$28.91M-$43.66M-$24.08M-$33.65M-$22.12M-$20.16M-$18.76M-$11.05M-$16.04M-$20.43M-$23.67M-$14.80M
    Capital expendituresN/AN/A$0$3.00K$57.00K$136.00K$0$0$0$0$0$64.00K
    Free cash flowN/AN/A-$24.08M-$33.65M-$22.18M-$20.30M-$18.76M-$11.05M-$16.04M-$20.43M-$23.67M-$14.86M
    Last 12 quarters

    Frequently Asked Questions About JBIO

    What is Jade Biosciences' annual revenue?

    Jade Biosciences reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Jade Biosciences profitable?

    No. Jade Biosciences reported net income of -$127.41M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does JBIO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$94.69M minus capital expenditures of $196.00K produced free cash flow of -$94.89M.

    How much debt does Jade Biosciences have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0 and cash and equivalents of $88.44M.